App for assessing the efficacy and safety of SAR442970 in moderate to severe HS.
Your app for the HS OBTAIN study with Sanofi assessing the efficacy and safety of an anti-TNF-OX40L NANOBODY molecule, SAR442970 in participants with moderate to severe hidradenitis suppurativa.
We use cookies and other technologies on this website to enhance your user experience. By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.